- In October 2023, Gilead Sciences, Inc. partnered with Assembly Biosciences to develop innovative therapeutics targeting severe viral diseases. This collaboration aims to leverage both companies' expertise and resources to accelerate the creation of effective treatment options. By combining their strengths, they seek to address critical unmet medical needs in the field of virology and improve patient outcomes
- In September 2023, Merck KGaA formed partnerships with BenevolentAI and Exscientia to utilize artificial intelligence in the drug discovery process. This collaboration focuses on developing new treatments in oncology, neurology, and immunology, aiming to identify innovative candidates for clinical development. By harnessing advanced AI technologies, Merck KGaA hopes to accelerate the discovery of groundbreaking therapeutic options
- In July 2023, Alexion and AstraZeneca Rare Disease entered into an agreement with Pfizer Inc. to acquire preclinical gene therapy programs. This collaboration reinforces their commitment to advancing next-generation genomic medicines by integrating complementary assets and innovative technologies. By pooling resources, the companies aim to accelerate the development of transformative therapies in the field of gene therapy
Frequently Asked Questions
Companies such as Abbott (U.S.), Agilent Technologies (U.S.), Danaher Corporation (U.S.), BD (U.S.), Bio-Rad Laboratories Inc. (U.S.), General Electric Company (U.S.), Hoefer, Inc. (U.S.), PerkinElmer Inc. (U.S.), Promega Corporation (U.S.), Quality Biological (U.S.), Bio-Techne (U.S.), and QuidelOrtho Corporation (U.S.); BIOMÉRIEUX (France); Lonza (Switzerland) and F. Hoffmann-La Roche Ltd. (Switzerland); Merck KGaA (Germany) and Siemens (Germany); and TAKARA HOLDINGS INC. (Japan), Sysmex Corporation (Japan), and Olympus Corporation (Japan) are the major companies in the biotechnology market.
In October 2023, Gilead Sciences, Inc. partnered with Assembly Biosciences to develop innovative therapeutics targeting severe viral diseases. In September 2023, Merck KGaA formed partnerships with BenevolentAI and Exscientia to utilize artificial intelligence in the drug discovery process. In July 2023, Alexion and AstraZeneca Rare Disease entered into an agreement with Pfizer Inc. to acquire preclinical gene therapy programs.
The countries covered in the biotechnology market are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Austria, Poland, Norway, Ireland, Hungary, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Philippines, Thailand, Malaysia, Vietnam, Indonesia, Singapore, rest of Asia-Pacific, Brazil, Argentina, Chili, Colombia, Peru, Venezuela, Ecuador, Uruguay, Paraguay ,Bolivia, Trinidad And Tobago, Curaçao, rest Of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, rest of Middle East and Africa, Guatemala, Costa Rica, Honduras, EL Salvador, Nicaragua, and rest of Central America.
